一、基本情況
鄧旭，湖北大悟人，教授，博士生導(dǎo)師，主要研究興趣是基于中藥來源活性天然產(chǎn)物的抗呼吸道感染新藥創(chuàng)制研究。曾入選湖南省杰青、湖南省衛(wèi)生健康高層次人才等；主持和承擔(dān)國家重點(diǎn)研發(fā)計(jì)劃子課題、國家自然科學(xué)基金面上項(xiàng)目、科技部高端外國專家引進(jìn)計(jì)劃、湖南省重點(diǎn)研發(fā)計(jì)劃等各類縱向課題10余項(xiàng)，以及企業(yè)產(chǎn)學(xué)研合作項(xiàng)目多項(xiàng)；在國際期刊發(fā)表高水平研究論文60余篇，其中以第一作者/通訊作者在Nature Comm., Angew. Chem. Int. Ed., J. Med. Chem.等高水平期刊發(fā)表SCI論文30余篇，總被引1500余次 (Google Scholar)，H指數(shù)24；以主要發(fā)明人申請專利20余項(xiàng)（包括PCT專利1項(xiàng)），其中12項(xiàng)已獲授權(quán)。此外，鄧旭博士還應(yīng)邀擔(dān)任Natural Products & Bioprospecting青年編委、國家自然科學(xué)基金委/廣東省/湖南省各類科技計(jì)劃項(xiàng)目評審專家，以及Adv. Sci., Theranostics, J. Med. Chem.等30余種學(xué)術(shù)期刊特邀審稿人，并榮獲2020年度德國Thieme Chemistry Journals Award國際學(xué)術(shù)獎和2023年度云南省自然科學(xué)二等獎1項(xiàng)。
熱忱歡迎熱愛天然藥物化學(xué)、有志于創(chuàng)新天然藥物研究的本科生、碩士生、博士生與博士后加入團(tuán)隊(duì)！
通訊地址: 長沙市岳麓區(qū)桐梓坡路172號湘雅醫(yī)學(xué)院藥學(xué)樓C608室
E-mails: dengxu3817@csu.edu.cn
個人網(wǎng)頁： https://faculty.csu.edu.cn/dengxu/zh_CN/index.htm
ORCID：https://orcid.org/0000-0001-7683-1626
二、研究領(lǐng)域
1. 基于中藥來源活性天然產(chǎn)物的抗呼吸道感染新藥創(chuàng)制研究；
2. 基于新穎結(jié)構(gòu)活性天然產(chǎn)物的化學(xué)生物學(xué)研究；
3. 活性天然產(chǎn)物合成（二萜、生物堿等）。
三、工作及學(xué)習(xí)經(jīng)歷
（一）教育經(jīng)歷
2007/9 - 2012/6，中國科學(xué)院昆明植物研究所，藥物化學(xué)，碩博連讀，導(dǎo)師：趙勤實(shí)研究員
2003/9 - 2007/6，中南大學(xué)，藥學(xué)，理學(xué)學(xué)士
（二）工作經(jīng)歷
2025/9 – 至今，中南大學(xué)，湘雅藥學(xué)院，教授，博士生導(dǎo)師
2018/9 – 2025/9，中南大學(xué)，湘雅藥學(xué)院，副教授，博士生導(dǎo)師
2018/12 – 2019/12，加拿大女王大學(xué)，訪問學(xué)者（合作導(dǎo)師：P. Andrew Evans教授）
2016/9 – 2018/9，中南大學(xué)，湘雅藥學(xué)院，講師，碩士生導(dǎo)師
2014/9 - 2016/08，武漢大學(xué)，化學(xué)與分子科學(xué)學(xué)院，博士后（合作導(dǎo)師：張緒穆教授）
2012/7 - 2014/8，中國科學(xué)院昆明植物研究所，植物化學(xué)與西部植物資源持續(xù)利用國家重點(diǎn)實(shí)驗(yàn)室，助理研究員
四、獲獎及榮譽(yù)
科研獲獎：
1. 德國Thieme Chemistry Journals Award（2020）
2. 2023年度云南省自然科學(xué)二等獎
教學(xué)獲獎：
1. 中南大學(xué)研究生教學(xué)成果二等獎（2022年度，排2）
2. 中南大學(xué)2017、2023年度教學(xué)質(zhì)量優(yōu)秀獎
3. 中南大學(xué)優(yōu)秀班導(dǎo)師（2018年度）
五、主持的代表性課題（負(fù)責(zé)人）
1. 國家重點(diǎn)研發(fā)計(jì)劃項(xiàng)目（參與，子課題負(fù)責(zé)人，2023YFC2606500），2024/01-2026/12
2. 國家自然科學(xué)基金面上項(xiàng)目（22377151），2024.01-2027.12
3. 科技部高端外國專家引進(jìn)計(jì)劃項(xiàng)目（G20200018017、G2021161003L、G2023161004L），2020.01-2024.12
4. 湖南省杰出青年基金（2023JJ10083），2023.1-2025.12
5. 湖南省重點(diǎn)研發(fā)計(jì)劃項(xiàng)目（2021WK2005），2021.09-2023.08
6. 國家自然科學(xué)基金青年項(xiàng)目（21302193），2014.01-2016.12
7. 湖南省自然科學(xué)基金面上項(xiàng)目（2021JJ30894），2021.01-2023.12
六、近5年的代表性專利（限10項(xiàng)）
(1) 發(fā)明人：鄧旭，曹東升，王慶，周應(yīng)軍，王森林，范金寶；《一種吲哚啉類化合物的制備方法》，授權(quán)公告日：2023-10-3；授權(quán)號：ZL2022106157434；
(2) 發(fā)明人：曹東升，鄧旭，田歡，吳炎，王慶，范金寶；《一種吲哚二聚體類化合物的制備方法》，授權(quán)公告日：2022-06-29；授權(quán)號：ZL202210646470.X；
(3) 發(fā)明人：鄧旭，周應(yīng)軍，楊舒婷，范金寶，寧帥，徐嘉浩，曾光堯；《獨(dú)角金內(nèi)酯衍生物在制備線粒體自噬抑制劑中的應(yīng)用》，授權(quán)公告日：2022-08-04；專利號：ZL202110893493.6；
(4) 發(fā)明人：鄧旭，周應(yīng)軍，曹偉，劉婷婷，楊舒婷，曾光堯；《Icetexane型松香烷二萜在制備結(jié)直腸癌治療藥物中的應(yīng)用》，授權(quán)公告日：2022-04-01；專利號：ZL202011641683.0；
(5) 發(fā)明人：鄧旭，周應(yīng)軍，曹偉，劉婷婷，楊舒婷，曾光堯；《一種Icetexane型松香烷二萜的制備方法》，授權(quán)公告日：2022-04-01；專利號： CN202011641565.X；
(6) 發(fā)明人：鄧旭，周應(yīng)軍，馬錦錦，李元建，曾光堯；《吳茱萸次堿-NO供體偶聯(lián)物及其應(yīng)用》，授權(quán)公告日：2018-11-06；專利號：ZL201811310581.3；
(7) 發(fā)明人：鄧旭，劉婷婷，周應(yīng)軍，嚴(yán)林洋，曹東升，曾光堯；《一種甲異靛衍生物的制備方法與應(yīng)用》，授權(quán)公告日：2023-08-13；專利號：ZL202210587486.8；
(8) 發(fā)明人：鄧旭，劉嫣蕓，李正澳，王森林，周宇箏，周應(yīng)軍，夏贊賢，曾光堯；《DNJ 衍生物、藥物組合物及其應(yīng)用》，授權(quán)公告日：2025-10-10；專利號：ZL202510035267.2.
(9). 發(fā)明人：李曉暉，鄧旭，殷明慧，馮雪祥，王森林、李瑩，周應(yīng)軍；DNJ及其衍生物在制備預(yù)防和/或治療肺動脈高壓藥物中的應(yīng)用；專利號：ZL202210433992.1.
(10) 發(fā)明人：周應(yīng)軍，曹偉，鄧旭，李元建，曾光堯；《鼠尾草酸或其衍生物在制備治療糖尿病并發(fā)癥藥物中的應(yīng)用》，授權(quán)公告日：2021-07-20；專利號： ZL202010716007.9；
七、近年來發(fā)表的代表性科研論文
(1) Tingting Liu#, Xingyue Chen#, Shah Nawaz Khan, Xiaoxu Li, Bo Kong, Yingjun Zhou, Yangyan Li, Yuhua Ge, Gang Chen*, Xu Deng*; Phytohormone Strigolactams Overcomes Oxaliplatin Resistance in Colorectal Cancer by Blocking the Late-Stage Autophagy to Tip the Metabolic Balance toward Ferroptosis. Journal of Medicinal Chemistry, 2025, 68 (22), 24546-24559.
(2). Ling-Fang Peng#, Kai-Qiang Fan #, Yu-Xing Zhou#, Tao Feng, Peng Zhan, Ying-Jun Zhou*, Xu Deng*; A Dehydrogenative Diels-Alder/Aromatization Sequence to Access 6/6/6/6/5 Pentacyclic Steroids: Their Anti-inflammatory Activities. Organic Letters, 2025, 27(6), 1335-1339.
(3). Yan-Yun Liu#, Zheng-Ao Li#, Yu-Zheng Zhou #, Sen-Lin Wang, Zong-Peng Chen, Si-Xu Liu, Peng Zhan, Ying-Jun Zhou, Zan-Xian Xia*, Xu Deng*; TCM theory-inspired discovery of DNJ-flavonoid conjugates as broad-spectrum anti-SARS-CoV-2 agents by primarily targeting ER-associated glycoprotein folding process. European Journal of Medicinal Chemistry, 2025, 290: 117582.
(4). Fan Zhou#, Dazhou Shi#, Baohu Li, Mei Wang, Shujing Xu*, Jinfei Yang*, Xu Deng*, Peng Zhan*; Antiviral strategies based on targeted protein degradation: an overview of the literature and future outlook. European Journal of Medicinal Chemistry, 2026, 301: 118208.
(5). Qiantong Liu#, Yanyun Liu#, Tingting Liu, Jinbao Fan, Zanxian Xia, Yingjun Zhou, Xu Deng*; Expanding horizons of iminosugars as broad-spectrum antivirals: mechanism, efficacy and novel developments. Natural Products & Bioprospecting, 2024, 14, 55.
(6). Tingting Liu#, Qing Wang #, Yuxin Zhou, Baixin Ye, Tingting Liu, Linyang Yan, Jinbao Fan, Yingjun Zhou, Zanxian Xia*, Xu Deng*; Discovery of a meisoindigo-derived PROTAC as the ATM degrader: revolutionizing colorectal cancer therapy via synthetic lethality with ATR inhibitors. Journal of Medicinal Chemistry, 2024, 67 (9), 7620-7634.
（7）Qingtian Gao#, Sixu Liu#, Yuzheng Zhou, Jinbao Fan, Shufen Ke, Yuqing Zhou, Kaiqiang Fan, Yuxuan Wang, Yingjun Zhou, Zanxian Xia*, Xu Deng*, Discovery of Meisoindigo derivatives as noncovalent and orally available Mpro inhibitors: their therapeutic implications in the treatment of COVID-19. European Journal of Medicinal Chemistry, 2024. 2024, 273, 11648.
（8）Jin-Bao Fan#, Liyang Shi#, Qing Wang, Yan Zeng, Wei Cao, Guangyao Zeng, Yingjun Zhou, Xu Deng*, RhI-Catalyzed Cycloisomerization Reactions of 1, 7-Enynes To Access Cage-Like Tricyclo [3.2. 2.06, 8] nonenes. Synthesis, 2024. 56, 2918-2924.
（9）Aroona Razzaq, Cyrollah Disoma, Yuzheng Zhou, Siyi Tao, Zongpeng Chen, Sixu Liu, Rong Zheng, Yongxing Zhang, Yujie Liao, Xuan Chen, Sijie Liu, Zijun Dong, Liangtao Xu, Xu Deng*, Shanni Li*, Zanxian Xia*, Targeting epidermal growth factor receptor signalling pathway: A promising therapeutic option for COVID‐19. Reviews in Medical Virology, 2024. 34, e2500.
（10）Moude Liu#, Qin Tang#, Qing Wang, Weixi Xie, Jinbao Fan, Siyuan Tang, Wei Liu, Yingjun Zhou*, Xu Deng*, Rapid access to icetexane diterpenes: their protective effects against lipopolysaccharides-induced acute lung injury via PI3K/AKT/NF-B axis in macrophages. European Journal of Medicinal Chemistry, 2023, 260, 115769.
(11). Yan Wu#, Moude Liu#, Qing Wang, Huan Tian, Jinbao Fan, Yingjun Zhou, Yajing Wang*, Xu Deng*; Divergent Synthesis of Bis(indolyl) methanes via FeIII catalyzed Regioselective Dehydrogenative Coupling Reactions: A Biomimetic Approach to 6,6’-bis-(debromo)-gelliusine F. Organic & Biomolecular Chemistry, 2023, 21, 639-643.
(12). Shuting Yang#, Jinbao Fan#, Tingting Liu#, Shuai Ning, Jiahao Xu, Yingjun Zhou*, Xu Deng*; Development of strigolactones as novel autophagy/mitophagy inhibitors against colorectal cancer cells by blocking the autophagosome-lysosome fusion. Journal of Medicinal Chemistry, 2022, 65, 9706-9713.
(13). Qing Wang, Senlin Wang, Jinbao Fan, Guangyao Zeng, Yingjun Zhou*, Xu Deng*; Acid-promoted intra- and intermolecular [2+2] cycloaddition of indoles with aryl alkynes to access cyclobutene-based indolines. Chemical Communications, 2022, 58, 9270-9273.
(14). Xu Deng#, Suling Huang#, Jian Ren, Zhenghong Pan, Yu Shen, Haofeng Zhou, Zhili Zuo*, Ying Leng*, Qinshi Zhao*; Development and structure-activity relationships of tanshinones as selective 11β-hydroxysteroid dehydrogenase 1 inhibitors. Natural Product & Bioprospecting, 2022, 12. 36.
(15). Wei Cao#, Tingting Liu#, Shuting Yang, Moude Liu, Zhenghong Pan, Yingjun Zhou*, Xu Deng*; Efficient synthesis of icetexane diterpenes and apoptosis inducing effect by upregulating Bip-ATF4-CHOP axis in colorectal cells. Journal of Natural Products, 2021, 84, 2012-2019.
（16）Xu Deng#, Li-Yang Shi#, Jia-ling Lan#, Yu-Qing Guan, Xiao-yong Zhang, Hui Lv*, Lung-Wa Chung*, Xu-mu Zhang*; Enantioselective rhodium-catalyzed cycloisomerization of 1,6-allenynes to access 5/6-fused bicycle[4.3.0]nonadienes, Nature Communications, 2019, 10, 949-959.
（17）Wei Cao, Jin-Bao Fan, Ling-Yang Yan, Guang-Yao Zeng, Jin-Jin Ma, Ya-Jing Wang, Ying-Jun Zhou*, Xu Deng*, Divergent reactivity in CuII-catalyzed oxidative coupling between indole/tryptamine derivatives and β-arylacrylic acids, Organic Letters, 2019, 21, 9506-9511.
（18）Jin-jin Ma#, Lan Chen#, Jin-bao Fan, Wei Cao, Guang-yao Zeng, Ya-jing Wang, Yuan-jian Li, Ying-jun Zhou*, Xu Deng*; Dual-targeting rutaecarpine-NO donor hybrids as novel anti-hypertensive agents by promoting release of CGRP, European Journal of Medicinal Chemistry, 2019, 168, 146-153.
（19）Xiaofeng Chen#, Jinbao Fan#, Guangyao Zeng, Jinjin Ma, Chenxi Wang, Yajing Wang, Yingjun Zhou*, Xu Deng*; Access to 3a-Benzoylmethyl Pyrrolidino[2,3-b]indolines via CuII-Catalyzed Radical Annulation/C3-Functionalization Sequence, The Journal of Organic Chemistry, 2018, 83, 8322-8330.
（20）Shuai Ning#, Lei Zhang#, Jin-jin Ma, Lan Chen, Guangyao Zeng, Yingjun Zhou, Xiaoli Guo*, Xu Deng*, Modular and scalable synthesis of nematode pheromone ascarosides: implications in eliciting plant defense, Organic & Biomolecular Chemistry, 2020, 18 (26), 4956-4961.
（21）Guang-yao Zeng, Zhao-quan Wu, Wei Cao,Ya-jing Wang, Yuan-jian Li, Xu Deng*, Ying-jun Zhou*; Identification of anti-nociceptive constituents from the pollen of Typha angustifolia L. using effect-directed fractionation. Natural Product Research, 2020, 34(7), 1041-1045.
